Reply

JACC. CardioOncology · Published 2026-07-01 · DOI 10.1016/j.jaccao.2026.05.011

Free full text

Authors (5)

Takuro Imaoka, Shingo Sakashita, Shohei Koyama, Ikuo Sekine, Kazuko Tajiri

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Citation

Imaoka, T., Sakashita, S., Koyama, S., et al. (2026). Reply. JACC. CardioOncology. https://doi.org/10.1016/j.jaccao.2026.05.011

Related articles

• CRISPR/Cas9 Screens Implicate RARA and SPNS1 in Doxorubicin Cardiotoxicity · JACC. CardioOncology · 2026 · Same journal
• Sacubitril/Valsartan in Anthracycline-Treated Patients · JACC. CardioOncology · 2026 · Same journal
• Major Adverse Cardiovascular Events and Cardiac Dysfunction in Patients With Acute Leukemia · JACC. CardioOncology · 2026 · Same journal
• Screened But Unproven · JACC. CardioOncology · 2026 · Same journal
• Treatment and Outcomes in Myocardial Infarction and Cancer—A German Real-Life Analysis · JACC. CardioOncology · 2026 · Same journal
• Sotatercept for the Treatment of Myeloproliferative Neoplasm–Associated Group 5 Pulmonary Hypertension · JACC. CardioOncology · 2026 · Same journal
• The Promise and Pitfalls of TTR Stabilization Assays in ATTR-CM · JACC. CardioOncology · 2026 · Same journal
• Elevated Plasma IL-18 Levels During Chemotherapy Treatment for Breast Cancer, Exercise Capacity, and Physical Activity · JACC. CardioOncology · 2026 · Same journal
• Proactive Surveillance for ICI Cardiotoxicity · JACC. CardioOncology · 2026 · Same journal
• Polygenic Risk Scores for Cardiovascular Risk Prediction in Breast Cancer Survivors · JACC. CardioOncology · 2026 · Same journal